ADAMTS13 and cancer: al. (2017), based on the criteria of the PLASMIC score, laboratory findings suggestive of a severe ADAMTS13 deficiency should report platelet count <30 x 109/L; MCV <90fL; absence of active cancer; absence of stem-cell transplant or solid-organ transplant; combined hemolysis variable assessed by reticulocyte count >2.5% or indirect bilirubin >2.0 mg/dL; INR <1.5; and creatinine <2.0 mg/dL where each finding corresponds to one score [6].